STARPHARMA HOLDINGS LIMITED (SPL)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
SPL - STARPHARMA HOLDINGS LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.36
Index: ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.36
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.13
22 Apr |
0.000 OPEN $0.13 |
0.000 HIGH $0.14 |
547,549 LOW $0.13 |
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . TLX . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -3.8 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 2.9 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 8.5 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -13.5 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -532.09 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -37.59 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -33.47 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -26.45 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -37.59 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -49.51 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -14.2 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 6 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 3 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 8 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 35 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 3.66 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.6 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 21.13 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 2 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 26 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 19 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
SPL STOCK CHART
FNArena News on SPL
1 |
Australian Broker Call *Extra* Edition – Nov 14, 2022Nov 14 2022 - Daily Market Reports |
2 |
Australian Broker Call *Extra* Edition – Sep 14, 2022Sep 14 2022 - Daily Market Reports |
3 |
Rudi’s View: August Results – First BloodAug 11 2022 - Rudi's View |
4 |
August In Review: Eleventh Month Of GainsSep 10 2021 - Australia |
5 |
February In Review: ASX Rises Five Consecutive MonthsMar 04 2021 - Australia |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
2 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
3 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
4 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
5 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
6 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
7 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
8 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
9 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |
10 |
Dr Boreham’s Crucible: Cleo DiagnosticsAug 30 2023 - Small Caps |